| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 28.25B | 26.14B | 24.45B | 21.55B | 17.48B |
| Gross Profit | 12.34B | 11.59B | 10.82B | 9.01B | 7.33B |
| EBITDA | 7.03B | 6.66B | 5.08B | 5.13B | 4.08B |
| Net Income | 3.63B | 3.30B | 3.27B | 2.78B | 2.39B |
Balance Sheet | |||||
| Total Assets | 41.11B | 38.89B | 34.29B | 29.77B | 24.88B |
| Cash, Cash Equivalents and Short-Term Investments | 1.88B | 1.52B | 1.59B | 1.70B | 1.51B |
| Total Debt | 10.99B | 10.36B | 9.52B | 8.26B | 6.91B |
| Total Liabilities | 21.83B | 20.48B | 18.96B | 16.43B | 14.12B |
| Stockholders Equity | 19.14B | 18.26B | 15.21B | 13.24B | 10.64B |
Cash Flow | |||||
| Free Cash Flow | 4.65B | 3.95B | 4.02B | 2.72B | 2.63B |
| Operating Cash Flow | 5.12B | 4.49B | 4.46B | 3.07B | 2.94B |
| Investing Cash Flow | -3.83B | -3.34B | -4.16B | -2.72B | -3.29B |
| Financing Cash Flow | -788.00M | -1.40B | -346.00M | -308.00M | 573.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | kr27.81B | 16.76 | 12.76% | 3.63% | 2.58% | 19.07% | |
69 Neutral | kr90.09B | 12.34 | 13.15% | 3.10% | -0.74% | 6.55% | |
62 Neutral | kr132.36B | 44.00 | 19.96% | 0.69% | 9.39% | 10.45% | |
58 Neutral | kr13.32B | 21.43 | 14.22% | 2.48% | 0.40% | 38.42% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | kr6.31B | 28.13 | 14.16% | 1.91% | 9.65% | 19.40% | |
45 Neutral | kr7.56B | 37.27 | -3.67% | 1.25% | 4.65% | -136.09% |
Lifco AB has agreed to acquire a majority stake in UK-based Ethoss Regeneration Ltd, a specialist in regenerative bone graft materials used in dentistry and oral surgery and sold globally. Ethoss, which generated about GBP 5.4 million in net sales in the year to July 2025 and employs 16 people in Silsden, England, will be integrated into Lifco’s Dental business area from the first quarter of 2026, with the transaction expected to have no significant impact on Lifco’s earnings or financial position for the current year, but to further strengthen its dental portfolio and niche positioning in advanced dental materials.
The most recent analyst rating on ($SE:LIFCO.B) stock is a Hold with a SEK326.00 price target. To see the full list of analyst forecasts on Lifco Ab stock, see the SE:LIFCO.B Stock Forecast page.
Lifco AB reported another year of earnings growth in 2025, with net sales up 8.1% to SEK 28.3 billion and EBITA rising 6.8% to SEK 6.3 billion, driven by both organic expansion and acquisitions despite negative currency effects. The EBITA margin remained robust at 22.4%, net profit increased 9.6%, cash flow from operating activities grew 10.7%, and the board proposed a higher dividend of SEK 2.70 per share, underscoring strong cash generation and shareholder returns. The group consolidated 16 new niche, market-leading businesses—six in Dental and ten in Systems Solutions—across several European countries, and with net debt at just 1.1 times EBITDA and ample MTN capacity, Lifco signalled significant headroom for further acquisitions to reinforce its buy-and-build strategy.
The most recent analyst rating on ($SE:LIFCO.B) stock is a Hold with a SEK326.00 price target. To see the full list of analyst forecasts on Lifco Ab stock, see the SE:LIFCO.B Stock Forecast page.
Lifco AB will publish its fourth-quarter and full-year 2025 results on 30 January at 7:30 a.m. CET, followed by a webcast and teleconference presentation at 9:00 a.m. CET with CEO Per Waldemarson and CFO Therése Hoffman. The scheduled report and investor presentation underscore Lifco’s ongoing communication with the capital market and provide an opportunity for analysts and investors to assess the performance and strategic progress of its diversified portfolio of niche businesses across dental, demolition & tools, and systems solutions segments.
The most recent analyst rating on ($SE:LIFCO.B) stock is a Hold with a SEK370.00 price target. To see the full list of analyst forecasts on Lifco Ab stock, see the SE:LIFCO.B Stock Forecast page.
Lifco AB has agreed to acquire all shares in Karl Kaps GmbH & Co. KG, a German niche manufacturer of medical and dental microscopes based in Asslar with 33 employees and 2024 net sales of about EUR 10.1 million. Karl Kaps will be integrated into Lifco’s Dental business area, with consolidation planned for the first quarter of 2026, and the deal is not expected to have a significant impact on Lifco’s earnings or financial position for the 2026 financial year, underscoring Lifco’s strategy of adding specialised, market‑leading companies to strengthen its dental portfolio without materially altering its overall financial profile.
The most recent analyst rating on ($SE:LIFCO.B) stock is a Hold with a SEK370.00 price target. To see the full list of analyst forecasts on Lifco Ab stock, see the SE:LIFCO.B Stock Forecast page.
Lifco AB has acquired DB Orthodontics Ltd, a UK-based company that produces and sells orthodontic materials to dental professionals globally. The acquisition, which will be consolidated into Lifco’s Dental business area in the fourth quarter of 2025, is not expected to significantly impact Lifco’s earnings or financial position this year.
The most recent analyst rating on ($SE:LIFCO.B) stock is a Hold with a SEK356.00 price target. To see the full list of analyst forecasts on Lifco Ab stock, see the SE:LIFCO.B Stock Forecast page.
Lifco AB’s Nomination Committee has proposed Anders Oscarsson for the Board of Directors, replacing Axel Wachtmeister, who will not seek re-election in 2026. Oscarsson’s extensive experience in equities and owner relations at AMF is expected to bring valuable insights to Lifco’s strategic direction, potentially impacting its operations and stakeholder relations positively.
The most recent analyst rating on ($SE:LIFCO.B) stock is a Hold with a SEK356.00 price target. To see the full list of analyst forecasts on Lifco Ab stock, see the SE:LIFCO.B Stock Forecast page.
Lifco AB has acquired a majority stake in HEGUtechnik GmbH, a German niche contract manufacturer specializing in electronic components for automation in harsh industrial environments. This acquisition, which will be consolidated into Lifco’s Business Area Systems Solutions, is not expected to significantly impact Lifco’s financials this year but strengthens its position in the contract manufacturing sector.
The most recent analyst rating on ($SE:LIFCO.B) stock is a Hold with a SEK390.00 price target. To see the full list of analyst forecasts on Lifco Ab stock, see the SE:LIFCO.B Stock Forecast page.